PMID- 31745220
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1473-1150 (Electronic)
IS  - 1470-269X (Linking)
VI  - 20
IP  - 2
DP  - 2020 Apr
TI  - Gender based differences, pharmacogenetics and adverse events in chronic pain 
      management.
PG  - 320-328
LID - 10.1038/s41397-019-0118-9 [doi]
AB  - Safety data in chronic non-cancer pain (CNCP) with long-term opioid therapy has 
      been poorly studied and can be differently influenced by gender. Furthermore, 
      pharmacogenetics (PGx) could possibly be used to tailor pain medication based on 
      the individual's genetic background. The aim was to assess whether PGx applied to 
      a pharmacovigilance system could help to improve a patient's security profile. A 
      pharmacovigilance data recording system was conducted over 24 months, including 
      genotyping of OPRM1 variants (opioid receptor, A118G) and COMT (enzyme that 
      degrades catecholamines such as norepinephrine, G1947A). Pain intensity (visual 
      analogue scale, VAS), morphine equivalent daily dose (MEDD), adverse events (AEs) 
      and suspected adverse drug reactions (ADRs) were recorded and analysed by gender. 
      The Ethics Committee approved the study and data were analysed with R 3.6.0 
      software. A total of 748 patients were recruited in the study (67% female, VAS 
      62 +/- 29 mm, MEDD 119 +/- 114 mg/day) reporting a median of 6 (3.5-9) AEs/patient. 
      Women presented more nausea, headaches, insomnia, loss of appetite, weight 
      change, depression and dizziness than men. Analysis by genotype demonstrated that 
      PGx influenced the prevalence of vomiting and depression in men, dizziness in 
      women and sexual dysfunction in both. Physicians notified 150 ADRs mostly in 
      females (79%) related to nervous system disorders. PGx applied to a 
      pharmacovigilance recording system provides important information to achieve a 
      better knowledge about AEs in CNCP pharmacological therapy. OPRM1 and COMT 
      polymorphisms were associated with AEs in CNCP patients that differed according 
      to gender.
FAU - Planelles, Beatriz
AU  - Planelles B
AD  - Pain Unit, Department of Health, Alicante General Hospital, Alicante, Spain.
AD  - Neuropharmacology apply to Pain and Functional Diversity (NED). ISABIAL-FISABIO 
      Foundation, General University Hospital of Alicante, Alicante, Spain.
FAU - Margarit, Cesar
AU  - Margarit C
AD  - Pain Unit, Department of Health, Alicante General Hospital, Alicante, Spain.
AD  - Neuropharmacology apply to Pain and Functional Diversity (NED). ISABIAL-FISABIO 
      Foundation, General University Hospital of Alicante, Alicante, Spain.
FAU - Inda, Maria-Del-Mar
AU  - Inda MD
AD  - Neuropharmacology apply to Pain and Functional Diversity (NED). ISABIAL-FISABIO 
      Foundation, General University Hospital of Alicante, Alicante, Spain.
FAU - Ballester, Pura
AU  - Ballester P
AD  - Neuropharmacology apply to Pain and Functional Diversity (NED). ISABIAL-FISABIO 
      Foundation, General University Hospital of Alicante, Alicante, Spain.
FAU - Muriel, Javier
AU  - Muriel J
AD  - Neuropharmacology apply to Pain and Functional Diversity (NED). ISABIAL-FISABIO 
      Foundation, General University Hospital of Alicante, Alicante, Spain.
FAU - Barrachina, Jordi
AU  - Barrachina J
AD  - Occupational Observatory, Miguel Hernandez University, Elche, Spain.
FAU - Ajo, Raquel
AU  - Ajo R
AD  - Neuropharmacology apply to Pain and Functional Diversity (NED). ISABIAL-FISABIO 
      Foundation, General University Hospital of Alicante, Alicante, Spain.
FAU - Esteban, Maria-Dolores
AU  - Esteban MD
AD  - Center of Operations Research, Miguel Hernandez University, Elche, Spain.
FAU - Peiro, Ana M
AU  - Peiro AM
AUID- ORCID: 0000-0002-2385-3749
AD  - Pain Unit, Department of Health, Alicante General Hospital, Alicante, Spain. 
      peiro_ana@gva.es.
AD  - Neuropharmacology apply to Pain and Functional Diversity (NED). ISABIAL-FISABIO 
      Foundation, General University Hospital of Alicante, Alicante, Spain. 
      peiro_ana@gva.es.
AD  - Clinical Pharmacology Unit, Department of Health, Alicante General Hospital, 
      Alicante, Spain. peiro_ana@gva.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191120
PL  - United States
TA  - Pharmacogenomics J
JT  - The pharmacogenomics journal
JID - 101083949
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics, Opioid/administration & dosage/*adverse effects
MH  - Chronic Pain/drug therapy/epidemiology/*genetics
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain Management/*methods
MH  - Pain Measurement/methods
MH  - Pharmacogenetics/*methods
MH  - Polymorphism, Single Nucleotide/genetics
MH  - *Sex Characteristics
MH  - Spain/epidemiology
EDAT- 2019/11/21 06:00
MHDA- 2021/03/30 06:00
CRDT- 2019/11/21 06:00
PHST- 2018/08/07 00:00 [received]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2019/10/08 00:00 [revised]
PHST- 2019/11/21 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2019/11/21 06:00 [entrez]
AID - 10.1038/s41397-019-0118-9 [pii]
AID - 10.1038/s41397-019-0118-9 [doi]
PST - ppublish
SO  - Pharmacogenomics J. 2020 Apr;20(2):320-328. doi: 10.1038/s41397-019-0118-9. Epub 
      2019 Nov 20.